Cargando…

A composite measure of cognitive and functional progression in Alzheimer's disease: Design of the Capturing Changes in Cognition study

INTRODUCTION: Cognitive testing in Alzheimer's disease (AD) is essential for establishing diagnosis, monitoring progression, and evaluating treatments. Assessments should ideally be brief, reliable, valid, and reflect clinically meaningful changes. There is a lack of instruments that meet all t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jutten, Roos J., Harrison, John, de Jong, Frank Jan, Aleman, André, Ritchie, Craig W., Scheltens, Philip, Sikkes, Sietske A.M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Featured Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651369/ https://www.ncbi.nlm.nih.gov/pubmed/29067324 http://dx.doi.org/10.1016/j.trci.2017.01.004

Ejemplares similares

The Cognitive‐Functional Composite is sensitive to clinical progression in early dementia: Longitudinal findings from the Catch‐Cog study cohort
por: Jutten, Roos J., et al.
Publicado: (2020)

A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test–retest reliability and feasibility
por: Jutten, Roos J., et al.
Publicado: (2017)

Assessing cognition and daily function in early dementia using the cognitive-functional composite: findings from the Catch-Cog study cohort
por: Jutten, Roos J., et al.
Publicado: (2019)

Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity
por: Jutten, Roos J., et al.
Publicado: (2021)

Neuropsychological Test Performance of Cognitively Healthy Centenarians: Normative Data From the Dutch 100‐Plus Study
por: Beker, Nina, et al.
Publicado: (2018)

Latent class analysis identifies functional decline with Amsterdam IADL in preclinical Alzheimer's disease
por: Villeneuve, Sarah-Christine, et al.
Publicado: (2019)

Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5
por: Papp, Kathryn V., et al.
Publicado: (2017)

Association of Cognitive Function Trajectories in Centenarians With Postmortem Neuropathology, Physical Health, and Other Risk Factors for Cognitive Decline
por: Beker, Nina, et al.
Publicado: (2021)

Cross-cultural adaptation and validation of the Amsterdam Instrumental Activities of Daily Living questionnaire short version German for Switzerland
por: Bruderer-Hofstetter, Marina, et al.
Publicado: (2020)

The relative efficiency of time-to-progression and continuous measures of cognition in presymptomatic Alzheimer's disease
por: Li, Dan, et al.
Publicado: (2019)

Detecting functional decline from normal aging to dementia: Development and validation of a short version of the Amsterdam IADL Questionnaire
por: Jutten, Roos J., et al.
Publicado: (2017)

Longitudinal Maintenance of Cognitive Health in Centenarians in the 100-plus Study
por: Beker, Nina, et al.
Publicado: (2020)

Decline in cognitively complex everyday activities accelerates along the Alzheimer’s disease continuum
por: Dubbelman, Mark A., et al.
Publicado: (2020)

Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab
por: Samtani, Mahesh N., et al.
Publicado: (2015)

Neuropathology and cognitive performance in self-reported cognitively healthy centenarians
por: Ganz, Andrea B., et al.
Publicado: (2018)

The effects of noncoding aquaporin-4 single-nucleotide polymorphisms on cognition and functional progression of Alzheimer's disease
por: Burfeind, Kevin G., et al.
Publicado: (2017)

Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease
por: Galasko, Douglas, et al.
Publicado: (2019)

Cognitive and structural cerebral changes in amnestic mild cognitive impairment due to Alzheimer's disease after multicomponent training
por: Teixeira, Camila Vieira Ligo, et al.
Publicado: (2018)

Telomere length associations with cognition depend on Alzheimer's disease biomarkers
por: Mahoney, Emily R., et al.
Publicado: (2019)

White matter hyperintensity topography in Alzheimer's disease and links to cognition
por: Garnier‐Crussard, Antoine, et al.
Publicado: (2021)

Clinical and cognitive characteristics of preclinical Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative cohort
por: Ihara, Ryoko, et al.
Publicado: (2018)

Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum
por: Tosun, Duygu, et al.
Publicado: (2021)

Comparison of serum neurodegenerative biomarkers among hospitalized COVID‐19 patients versus non‐COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia
por: Frontera, Jennifer A., et al.
Publicado: (2022)

Neural and behavioral substrates of disorientation in mild cognitive impairment and Alzheimer's disease
por: Sousa, Amber, et al.
Publicado: (2015)

Cognitive measures lacking in EHR prior to dementia or Alzheimer's disease diagnosis
por: Maserejian, Nancy, et al.
Publicado: (2021)

Economic impacts of introducing diagnostics for mild cognitive impairment Alzheimer's disease patients
por: Wittenberg, Raphael, et al.
Publicado: (2019)

Social cognition deficits and biometric signatures in the behavioural variant of Alzheimer’s disease
por: Singleton, Ellen H, et al.
Publicado: (2022)

Sequences of cognitive decline in typical Alzheimer's disease and posterior cortical atrophy estimated using a novel event‐based model of disease progression
por: Firth, Nicholas C., et al.
Publicado: (2020)

The Cognitive Ageing, Nutrition and Neurogenesis (CANN) trial: Design and progress
por: Irvine, Michael A., et al.
Publicado: (2018)

Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal‐Dominant Alzheimer's Disease Colombia Trial
por: Rios‐Romenets, Silvia, et al.
Publicado: (2020)

Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2019)

Lower practice effects as a marker of cognitive performance and dementia risk: A literature review
por: Jutten, Roos J., et al.
Publicado: (2020)

The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design
por: Bertens, Daniela, et al.
Publicado: (2017)

Identification of prognostic factors to predict cognitive decline of patients with early Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative study
por: Yagi, Takuya, et al.
Publicado: (2019)

Awareness of Cognitive Decline in Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis
por: Cacciamani, Federica, et al.
Publicado: (2021)

Cross-validation of optimized composites for preclinical Alzheimer's disease
por: Donohue, Michael C., et al.
Publicado: (2016)

Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2016)

Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study
por: Lopes Alves, Isadora, et al.
Publicado: (2020)

Rates of longitudinal change in (18)F‐flortaucipir PET vary by brain region, cognitive impairment, and age in atypical Alzheimer's disease
por: Phillips, Jeffrey S., et al.
Publicado: (2021)

Marked gender differences in progression of mild cognitive impairment over 8 years
por: Lin, Katherine A., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_89s2m65csu5pf97n65d72qqd4c